LVIS EVO支架辅助弹簧圈栓塞治疗颅内动脉瘤:长期随访结果
单中心回顾性分析2021年1月至2024年1月连续34例未破裂颅内动脉瘤患者使用LVIS EVO支架辅助弹簧圈栓塞,支架成功释放率100%,中位影像随访24个月时91.2%动脉瘤完全闭塞、97.1%充分闭塞,并发症率低,末次随访mRS≤2者100%。
要点
- LVIS EVO支架释放成功率100%,中位随访24个月完全闭塞率91.2%、充分闭塞率97.1%。
- 围手术期支架内血栓2例(5.9%)均处理成功,无症状性支架内狭窄2例(5.9%)。
- 无出血性或永久性缺血并发症,末次临床随访mRS≤2者100%。
核心结论
- LVIS EVO支架技术成功率高、动脉瘤闭塞持久且并发症率低,支持其用于颅内动脉瘤(包括既往破裂病灶和解剖复杂部位)治疗的安全性和有效性。
研究设计与样本
- 单中心回顾性分析,2021年1月至2024年1月连续34例未破裂颅内动脉瘤患者(34个囊状动脉瘤)接受LVIS EVO支架辅助弹簧圈栓塞,收集基线人口学、影像和手术特征、临床结局及临床和影像随访数据。
诊断标准与关键数值
- 主要终点为支架成功释放及随访时按Raymond-Roy闭塞分级(RROC)评估的动脉瘤完全闭塞;次要终点包括并发症率、末次临床随访mRS和末次随访影像支架内狭窄发生率。
临床应用与阅片要点
- 原文结论认为结果支持LVIS EVO支架在颅内动脉瘤治疗中的安全性和有效性,包括既往破裂病灶和解剖复杂部位。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: The Low-profile visualized Intraluminal Support EVO (LVIS EVO) is a next-generation braided stent characterized by enhanced visibility and resheathability, and designed for stent-assisted coil embolization of intracranial aneurysms. Despite growing adoption, real-world data on its efficacy and safety remain limited.
OBJECTIVE: This study aims to evaluate the safety and efficacy of the LVIS EVO stent in consecutive patients undergoing treatment for brain aneurysms.
METHODS: We retrospectively analyzed all patients who underwent treatment of unruptured intracranial aneurysms with the LVIS EVO stent in a single tertiary center between January 2021 and January 2024. Baseline demographics, imaging and procedural characteristics, clinical outcomes, and clinical and radiological follow-up data were collected. The primary endpoints were successful deployment and complete aneurysm occlusion at follow-up as defined by the Raymond-Roy Occlusion Classification. Secondary endpoints included complication rate, modified Rankin Scale (mRS) at last clinical follow-up, and incidence of in-stent stenosis on last follow-up imaging.
RESULTS: Thirty-four patients (64.7% women; median age: 52 years) were treated for 34 saccular aneurysms. Most of the aneurysms were previously ruptured and recanalized after initial treatment (20/34, 58.8%). They were mainly located at the middle cerebral artery (15/34, 44.1%) and the internal carotid artery terminus (8/34, 23.5%), with additional cases at the anterior communicating artery (7/34, 20.6%) and the posterior circulation (4/34, 11.8%). Median aneurysm neck size was 3.3 mm, with an aspect ratio of 1.2 and a dome-to-neck ratio of 1.3. Stent deployment was successful in 100% of cases. Immediate complete occlusion (RROCs I) was achieved in 82.4% of aneurysms. At a median radiological follow-up of 24 months, 91.2% of aneurysms remained completely occluded, and 97.1% were adequately occluded (RROC I-II). Two intraprocedural cases (5.9%) of in-stent thrombosis occurred and were managed successfully. One post-procedural symptomatic ischemic event occurred, but the patient was asymptomatic at the last clinical follow-up. There were no hemorrhagic or permanent ischemic complications. Asymptomatic in-stent stenosis occurred in 2 patients (5.9%). Clinical outcome was favorable (mRS ≤ 2) in 100% of cases at last follow-up.
CONCLUSION: The LVIS EVO stent demonstrates excellent technical success and sustained aneurysm occlusion with a low complication rate. These results support its safety and efficacy in the treatment of intracranial aneurysms, including previously ruptured lesions and anatomically complex locations.
引用
- Wei F, Geismar M, Kalsoum E, et al. LVIS EVO stent-assisted coiling for intracranial aneurysms: results of long-term follow-up. Neuroradiology. 2025. PMID: 41251772. doi:10.1007/s00234-025-03808-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。